20133-Lymphomas-Non-Hodgkins-150

Lymphomas

MOR208C310: A Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

  • Details

ClinicalTrials.gov ID: NCT04824092
Diagnosis Type: Non-Hodgkins
USOR Number:

  • Address

520 Country Club Rd
Eugene, OR 97401
P: (541) 683-5001

Search by practice name, trial titles, indicators and specific disease types.